WHO Collaborating Centre for Drug Information, National Poison Centre, Universiti Sains Malaysia (USM), Penang, Malaysia.
Fundam Clin Pharmacol. 2011 Jun;25(3):405-10. doi: 10.1111/j.1472-8206.2010.00831.x.
Intravenous N-acetylcysteine (IV-NAC) is usually regarded as a safe antidote to acetaminophen overdose. However, during infusion of the loading dose, adverse drug reactions such as a headache may occur. The objectives of this study were to investigate the prevalence of headache in patients presenting to hospital after acetaminophen overdose and to determine which clinical findings are most predictive of headache among these patients. This is a retrospective cohort study of hospital admissions for acute acetaminophen overdose that was conducted over a period of 4 years from January 1, 2005 to December 31, 2008. Demographic data, clinical characteristics, and predictors of headache were analyzed. spss 15 was used for data analysis. Two-hundred and fifty-five patients were studied; their mean age was 23.1 ± 1.6; 83.9% of them were women and 14.9% had a headache during hospitalization. Headache among patients was significantly associated with IV-NAC administration (P = 0.001), intentional ingestion of drug (P = 0.04), acetaminophen concentration above 'possible toxicity' treatment line (P = 0.04), a high acetaminophen concentration (P = 0.04), and a long hospital stay (P = 0.03). Multiple logistic regression showed a significant risk factor for headache in patients administered IV-NAC (P = 0.04). We recorded a high frequency of headache in patients with acute acetaminophen overdose in our geographical area. This study suggests that among those patients, the use of IV-NAC is associated with an increased risk of headache.
静脉注射 N-乙酰半胱氨酸(IV-NAC)通常被认为是对乙酰氨基酚过量的安全解毒剂。然而,在输注负荷剂量期间,可能会出现不良反应,如头痛。本研究的目的是调查在医院就诊的乙酰氨基酚过量患者中头痛的发生率,并确定这些患者中哪些临床特征最能预测头痛。这是一项回顾性队列研究,研究对象为 2005 年 1 月 1 日至 2008 年 12 月 31 日期间因急性乙酰氨基酚过量住院的患者。分析了人口统计学数据、临床特征和头痛的预测因素。使用 spss 15 进行数据分析。共研究了 255 例患者;他们的平均年龄为 23.1 ± 1.6;83.9%为女性,14.9%在住院期间有头痛。头痛与 IV-NAC 给药(P = 0.001)、故意服用药物(P = 0.04)、乙酰氨基酚浓度高于“可能毒性”治疗线(P = 0.04)、高乙酰氨基酚浓度(P = 0.04)和住院时间长(P = 0.03)显著相关。多因素逻辑回归显示 IV-NAC 给药的患者头痛的显著危险因素(P = 0.04)。我们记录了我们所在地区急性乙酰氨基酚过量患者头痛的高发生率。本研究表明,在这些患者中,使用 IV-NAC 与头痛风险增加相关。